摘要
重症肌无力是一种影响突触后膜的自身免疫性疾病，病态疲劳性肌无力为主要特点。近年来较多研究显示多种免疫抑制剂和单克隆抗体对重症肌无力的治疗具有重要作用。进一步熟知难治性重症肌无力的治疗进展对于改善患者的临床症状具有深远意义。
Myasthenia gravis is an acquired autoimmune disease, which influences the postsynaptic membrane and makes affected muscle pathological fatigue. In recent years, many research results show that a va- riety of immune inhibitors and monoclonal antibody play an important role in the treatment of myasthenia gravis. Having a good knowledge of the treatment of refractory myasthenia gravis lay a foundation for improving the clin- ical manifestations.
出处
《国际免疫学杂志》
CAS
2017年第2期216-220,共5页
International Journal of Immunology
基金
山西省卫生计生委科研项目（2015030）
关键词
难治性重症肌无力
单克隆抗体
免疫抑制剂
手术
Refractory myasthenia gravis
Monoclonal antibody
Immune inhibitors
Surgery
